Landos Biopharma Inc (LABP) Return on Equity ROE from the first quarter 2024 to first quarter 2023 and annually, average high and low, overall ranking from Mar 31 2024 to Mar 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Landos Biopharma Inc   (NASDAQ: LABP)

Landos Biopharma Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Landos Biopharma Inc in the first quarter 2024?
Landos Biopharma Inc recorded a cumulative net loss of $-25 million during 12 months ending in the first quarter 2024, resulting in a negative return on equity (ROE) of -73%.

Within the Major Pharmaceutical Preparations industry 11 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2023 from 180 to 183.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter
Y / Y Equity Change -50.76 % -18.76 % -14.43 % -16.03 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -25 -22 -21 -23 -30
Return On Equity (TTM) -73 % -54.92 % -50.39 % -53.24 % -67.03 %
LABP's Total Ranking # 183 # 180 # 2013 # 3288 #
Equity (TTM) in Millions 23 32 38 43 47
Seq. Equity Change -27.17 % -15.59 % -12.96 % -7.98 % 20.17 %
Seq. Net Income Change - - - - -

Back to LABP Management Effectiveness >> LABP's 5 Years Annual ROE >> Compare LABP ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 12
Sector # 32
Overall # 183

Return On Equity Statistics
High Average Low
48.49 %
-16.08 %
-51.46 %
(Dec 31 2023)   (Mar 31 2022)





LABP Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021

Total Equity in Millions 32 39 76 0 0
Y / Y Equity Change -18.76 % -48.69 % - - -
Net Income in Millions -22 -39 -38 0 0
Y / Y Net Income Change - - - - -
Return On Equity -69 % -100.37 % -50.38 % - -

Back to LABP Management Effectiveness >> LABP's 5 Years Annual ROE >> Compare LABP ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LABP's' Return on Equity at Yahoo Finance
LABP's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LABP's Competitors
Subscribers only: Roe for Landos Biopharma Inc 's Suppliers
Subscribers only: Return On Equity for LABP's Customers




Companies with similar Return On Equity at Mar 31 2024, within Healthcare Sector ROE

Date modified: 2026-09-08T15:22:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.